L'esfal (L'esfal)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substancePhospholipidsPhospholipids
Similar drugsTo uncover
  • Antralive®
    capsules inwards 
    Nizhny Novgorod Chemical and Pharmaceutical Plant, OJSC    
  • L'esfal
    solution in / in 
    FARMAK, PAO     Ukraine
  • Livenciale
    solution in / in 
    Rowecq Limited     United Kingdom
  • Livolife Forte
    capsules inwards 
    KORAL-MED, CJSC     Russia
  • Phosphontsiale®
    capsules inwards 
    CANONFARMA PRODUCTION, CJSC     Russia
  • Phosphontsiale® Mono
    solution in / in 
    Bakter, OOO     Russia
  • Essentiale® H
    solution in / in 
    AVENTIS PHARMA, CJSC     Russia
  • Essentiale® Fort H
    capsules inwards 
    A. Nattermann and Sie. GmbH     Germany
  • Essential phospholipids
    capsules inwards 
    ATOLL, LLC     Russia
  • Essley forte
    capsules inwards 
    ATOLL, LLC     Russia
  • Essley®
    solution in / in 
    Outline Pharma Pvt. Ltd.     India
    • Dosage form: & nbsp

    solution for intravenous administration.


    Composition:

    1 ml of solution:

    Active substance: phosphatidylcholine from soybeans - 50.0 mg;

    Excipients: gasoline - 9.00 mg; deoxycholic acid - 25.30 mg; sodium chloride - 2.36 mg; sodium hydroxide - 2.86 mg; riboflavin - 0.10 mg; water for injection - up to 1.0 ml.

    Description:clear yellow solution
    Pharmacotherapeutic group:hepatoprotective agent
    ATX: & nbsp

    A.05.C   Combination of drugs for the treatment of diseases of the liver and biliary tract

    Pharmacodynamics:Phospholipids, contained in the preparation, are similar in their chemical structure to endogenous phospholipids, but far exceed their content of polyunsaturated (essential) fatty acids.These high-energy molecules are built primarily into the structures of cell membranes and facilitate the restoration of damaged liver tissue. Phospholipids affect the impaired lipid metabolism by regulating the metabolism of lipoproteins, as a result of which neutral fats and cholesterol are converted into forms suitable for transportation, especially due to the increase in the ability of high-density lipoproteins (HDL) to attach cholesterol, and are intended for further oxidation. During the removal of phospholipids through the biliary tract, the lithogenic index decreases and bile stabilization occurs.
    Pharmacokinetics:
    Linking mainly with high-density lipoproteins, phosphatidylcholine enters in particular into liver cells.
    The half-life for the choline component is 66 hours, for unsaturated fatty acids - 32 hours.

    Indications:
    Fatty liver degeneration, acute and chronic hepatitis, liver cirrhosis, hepatic coma and precoma, pre- and postoperative treatment for surgical interventions in the hepatobiliary zone, toxic liver damage, pregnancy toxicity,psoriasis (as an auxiliary therapy), radiation syndrome.

    Contraindications:
    Hypersensitivity to the components of the drug. Intolerance to soy.
    Children under 12 years.

    Carefully:
    Pregnancy, children age over 12 years.

    Pregnancy and lactation:
    In pregnancy, due to the presence of a petrol alcohol in the formulation that can penetrate the placental barrier (the use of drugs containing petrol alcohol in newborn babies or premature newborns was associated with the development of dyspnoeal syndrome with a fatal outcome), the drug can only be used in cases where the expected benefit to the mother exceeds the potential risk to the fetus.
    It is not recommended to use during breastfeeding due to the lack of data on the safety of the drug.

    Dosing and Administration:
    Only use a clear solution.
    Do not administer the drug intramuscularly because of a possible local reaction.
    The drug is administered intravenously slowly 5-10 ml per day, in severe cases from 10-20 ml per day. At once allow 10 ml of the drug.To dilute the drug is recommended to use the patient's own blood in a ratio of 1: 1. The course of treatment is up to 10 days with the subsequent transition to oral forms of phosphatidylcholine.
    Treatment of psoriasis begins with taking oral forms of phosphatidylcholine for 2 weeks. After that, 10 intravenous injections of 5 ml are recommended with the simultaneous administration of PUVA therapy. After the end of the injection course, the administration of oral forms of phosphatidylcholine is resumed.
    In cases where it is impossible to use the patient's own blood to dilute the drug, solutions that are free of electrolytes - 5% or 10% glucose solution, 5% xylitol solution in a ratio of 1: 1 should be used.

    Side effects:
    From the gastrointestinal tract: discomfort in the epigastric region, loosening of the stool, nausea, gastralgia.
    From the immune system: allergic reactions (rash, exanthema, urticaria, skin itching).

    Overdose:There were no reports of an overdose.
    Interaction:
    Interaction with other drugs has not been studied. The drug is not compatible with electrolyte solutions. Do not administer the drug with other medicines in the same syringe.

    Special instructions:
    Use only a clear solution!
    Caution: the solution contains benzyl alcohol.
    Only for intravenous use.
    Children. The drug is used to treat children older than 12 years.
    Effect on the ability to drive transp. cf. and fur:Not detected
    Form release / dosage:Solution for intravenous administration 50 mg / ml.

    Packaging:
    5 ml per ampoule of brown glass of the first hydrolytic class with a ring of fracture or break point. On the ampoules stick labels self-adhesive. For 5 or 10 ampoules, together with the instructions for use, they are put in a bundle with corrugated cardboard inserts. Or 5 ampoules are put in a blister of polymer film. For I or 2 blisters with ampoules, along with instructions for use, are put in a pack of cardboard.

    Storage conditions:
    Store in a dark place at a temperature of 2 ° C to 8 ° C.
    Keep out of the reach of children.

    Shelf life:
    2 years. Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:11.09.2015
    The owner of the registration certificate:FARMAK, PAO FARMAK, PAO Ukraine
    Manufacturer: & nbsp
    Representation: & nbspFARMAK PAOFARMAK PAO
    Information update date: & nbsp28.10.2015
    Illustrated instructions
      Instructions
      Up